Stay updated on HMPL-523 in Lymphoma Patients Clinical Trial
Sign up to get notified when there's something new on the HMPL-523 in Lymphoma Patients Clinical Trial page.

Latest updates to the HMPL-523 in Lymphoma Patients Clinical Trial page
- ChecktodayChange DetectedThe record no longer lists a 2026 *Blood Advances* article reporting the Phase 1 study of sovleplenib (HMPL-523) in relapsed or refractory lymphoma, along with the note explaining that publications are drawn from PubMed.SummaryDifference0.2%

- Check7 days agoChange DetectedThe clinical trial record for HMPL-523 in relapsed or refractory lymphoma is now available, with study design, eligibility criteria, locations, and outcome measures. It states that the study was terminated by the sponsor and is no longer recruiting, and includes posted results and study documents.SummaryDifference74%

- Check14 days agoChange DetectedThe footer’s revision identifier changed from v3.7.2 to v3.8.0. The study record area still displays a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It appears above the study page’s 403 error.SummaryDifference1%

- Check28 days agoChange DetectedThe footer's site revision label updates from v3.7.1 to v3.7.2 while the page remains a 403 error screen.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to HMPL-523 in Lymphoma Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HMPL-523 in Lymphoma Patients Clinical Trial page.